These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effects of long-term treatment with the 5-HT1A receptor agonist 8-OH-DPAT and the 5-HT2/1C receptor agonist DOI in the neonatal rat.
    Author: Johansson-Wallsten CE, Berg M, Meyerson BJ.
    Journal: Eur J Pharmacol; 1993 Oct 19; 243(2):149-54. PubMed ID: 8276064.
    Abstract:
    The rat pup ultrasonic call was used to study the effects of acute and long-term treatment with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and the 5-HT2/1C receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) during the neonatal period. Acute administration of 8-OH-DPAT and DOI reduced the number of ultrasonic calls. The reduction induced by 8-OH-DPAT and DOI was antagonized by the 5-HT1A antagonist (S)-5-fluoro-8-hydroxy-2-(di-n-propylamino)tetralin ((S)-UH-301) and the 5-HT2 antagonist ketanserin, respectively. The long-term treatments were started on postnatal day 1. On postnatal day 7, the response of the long-term DOI-treated group was clearly attenuated in comparison to that of the acute DOI-treated group. In contrast, no tolerance to the effect of 8-OH-DPAT was achieved after an analogous treatment. The data indicate that there is a diversity in the ontogeny of the ability to develop tolerance to 5-HT1A agonists in comparison to 5-HT2/1C agonists.
    [Abstract] [Full Text] [Related] [New Search]